Immunotherapy plus chemo before surgery for esophagus cancer
Part of Cancer, Digestive system clinical trials.
This Phase 2 study tests a new immunotherapy drug (candonilimab/AK104) added to chemotherapy before surgery for people with locally advanced esophageal squamous cell carcinoma. It aims to shrink the cancer and improve outcomes by treating it before the operation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can sign informed consent and are age 18 to 70
- Your cancer is esophageal squamous cell cancer confirmed by pathology (biopsy)
- Your scans show no spread to distant organs, and the tumor can be removed or possibly removed
- You have not had any prior cancer treatment for esophageal cancer (chemo, radiation, surgery, or immunotherapy)
- Your overall health is strong enough for treatment (good organ function and an ECOG of 0–1)
- You must not have certain high-risk situations (like major vessel involvement or high bleeding/perforation risk) and must not be pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called Adebrelimab combined with chemotherapy before surgery for esophageal cancer. It aims to shrink the tumor and make it easier to remove completely.
This study tests whether giving a combination of chemotherapy, radiation, and an immunotherapy drug (cadonilumab) before surgery can help shrink esophageal cancer and improve outcomes. It is for people with a specific type of esophageal cancer that has not spread to other parts of the body.
This trial tests a new immunotherapy drug (ivonescimab, also called AK112) combined with chemotherapy before surgery for people with esophageal squamous cell cancer that can be completely removed. The goal is to see if adding immunotherapy before surgery helps shrink the tumor and improve outcomes.
This trial tests a combination of two targeted drugs (nimotuzumab and camrelizumab) plus standard chemotherapy before surgery for people with esophageal squamous cell carcinoma. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests if giving chemotherapy and radiation before surgery, followed by immunotherapy, can improve outcomes for people with a specific type of esophageal cancer that can be surgically removed.
This trial studies giving immunotherapy (anti–PD-1) together with chemotherapy before surgery for certain locally advanced esophageal squamous cell cancer. The goal is to improve how well the tumor responds before and after the operation.
Hear when a new Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.